Programs Include a Systematic Approach to Drug
Repurposing & Data-Driven, Proactive Chronic Disease Management
-- Both Fueled by the IBM Watson Health Cloud
Collaboration Features First Integration of The
Weather Company data with IBM Watson Health Cloud
IBM (NYSE:IBM) and Teva Pharmaceutical Industries Ltd., (NYSE
and TASE:TEVA) today announce a significant expansion of their
existing global e-Health alliance with a focus on two key
healthcare challenges: the discovery of new treatment options and
improving chronic disease management. Both projects will run on the
IBM Watson Health Cloud.
The expanded partnership features a new, three-year research
collaboration to develop cognitive technologies that can enable a
systematic approach to the emerging field of drug repurposing and
deliver unprecedented scale in the discovery of new uses for
existing drugs. The companies also announced that respiratory and
central nervous system (CNS) diseases will be the first targets for
their chronic disease management initiative, which will be the
first project to integrate data from The Weather Company (an IBM
Business) into the analysis. The joint work in chronic disease
management emerges from Teva’s existing alliance with IBM as a
Foundational Life Sciences Partner for the IBM Watson Health
Cloud.
Today’s announcement is made in conjunction with a presentation
on the main stage at the World of Watson conference by Professor
Yitzhak Peterburg, Teva’s Chairman of the Board of Directors,
alongside IBM Chairman, President and CEO Ginni Rometty. “Teva’s
products reach 200 million people every day with the world's
largest medicine cabinet. We have the opportunity to lead change in
the pharmaceutical industry, innovating constantly to meet
consumers' evolving needs. By combining the skills of our partners,
such as Watson's cognitive computing capabilities, with Teva's
pharmaceutical expertise, we can create novel solutions and deliver
real value to people,” said Professor Peterburg.
“Working together, Teva and IBM create an unprecedented
opportunity to help doctors and patients worldwide achieve the
promise of personalized healthcare,” said Deborah DiSanzo, general
manager for IBM Watson Health. “IBM and Teva’s announcements today
are notable for two reasons. First, IBM’s work with Teva extends
from the biopharmaceutical research bench to an individual’s
medicine cabinet -- underscoring the power of Watson cognitive
computing across life sciences and healthcare. Second, this work
includes the first integration of data from The Weather Company
with the Watson Health Cloud, a milestone and demonstrable of how
the definition of ‘health data’ is evolving.”
A Systematic Approach to Discovering New Uses for Existing
Drugs
Thirty percent of regulatory approvals by the FDA in recent
years have been for new uses of previously approved drugs and
vaccines1. A repurposing approach to drug discovery and
development is intended to streamline the time- and cost-intensive
process of bringing new therapies to market, which can take the
industry up to 20 years and cost in excess of $2.5 billion.
Medicines that have regulatory clearance have been comprehensively
tested, resulting in known safety and efficacy profiles which may
significantly reduce the drug development burden. New uses,
formulations and delivery innovations for previously approved
medicines have the potential to come to market quickly and
efficiently and address unmet medical needs.
Currently, the discovery of new therapeutic uses for existing
medicines is largely the result of serendipitous findings or
isolated research. The aim of the new collaboration between Teva
and IBM Research is to design, build, and deploy a systematic
process for drug repurposing, potentially becoming a blueprint for
use across the industry. The process will combine human insight
with unique machine-learning algorithms and real-world evidence
accessed through the IBM Watson Health Cloud. IBM Watson Health
Cloud technology will be applied on a massive scale with the aim of
revealing previously hidden correlations between a drug molecule
and health conditions.
“Teva is a leader in innovation using existing molecules and IBM
has pioneered Watson cognitive computing – it is a natural
partnership,” said Michael Hayden, Teva's President of Global
R&D and Chief Scientific Officer. “This collaboration will
bring together the science and the technology to scale up
‘serendipity’ to an industrial level, opening up new and exciting
possibilities to create novel treatments for patients based on
existing medicines.”
“There is so much data out there that is currently
underutilized, yet has the potential to significantly inform drug
repurposing. Eighty percent of all health data is invisible to
current technology systems because it’s unstructured,” said Ajay
Royyuru, IBM Fellow and Director of Healthcare & Life Sciences
for IBM Research. “Using cognitive technologies to mine this data
could reveal novel therapies for diseases that desperately need
tackling. By teaming up with Teva, our belief is we will gain
insights that can lead pharmaceutical companies to develop new
medicines that benefit patients worldwide.”
Empowering Doctors and Patients to Manage Chronic
Diseases
Chronic diseases present a global burden, both on patients and
on our healthcare systems. Widespread chronic diseases, like
asthma, which is estimated to impact 400 million people around the
world by 2025, remain uncontrolled in many patients despite decades
of availability to proven medications. Many people living with
asthma, for example, still experience uncontrolled symptoms and
frequent attacks – often due to incorrect inhaler use or poor
adherence to treatment. The need exists for therapeutic solutions
that enable a systematic, comprehensive approach to help people
take control of their health conditions.
To address the global impact of chronic diseases, Teva and IBM
reveal, for the first time, that they are working together on an
initiative that combines Teva’s therapeutic technologies with IBM
Watson’s cognitive computing. Together, the companies aim to enable
patients, healthcare providers, and payers to better understand and
control chronic conditions, and track treatments.
The chronic disease management collaboration will combine
cloud-connected drug delivery and app technology with more than six
billion data points processed by Watson to provide actionable
insights, including the first-ever integration of data from The
Weather Company. Using Watson’s cognitive processing capabilities
and newly developed algorithms these data may be used to calculate
the prospective risk of health events, such as an asthma attack,
with Teva delivering that information directly to caregivers and
their patients via an app or other software interface.
“Teva envisions a future where we can empower patients and their
families to better understand diseases, like asthma, and cope with
health challenges in a more systematic, data-driven manner, with
the ability to be proactive, rather than reactive,” said Rob
Koremans, MD, President and CEO of Teva Global Specialty Medicines.
“In doing so, we aim to cut treatment costs by providing patients,
payers, healthcare providers and caregivers with relatable data
that can inform action and insights into a patient’s total disease
management plan.”
The IBM Watson Health Cloud is a health-data enabled
platform-as-a-service. It provides a foundation for cognitive
offerings and is designed to help healthcare organizations derive
individualized insights and obtain a more complete picture of
the many factors that can affect people’s health. Teva’s use of the
IBM Watson Health Cloud will comply with operational and security
requirements for health data.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
leading global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients
every day. Headquartered in Israel, Teva is the world’s largest
generic medicines producer, leveraging its portfolio of more than
1,800 molecules to produce a wide range of generic products in
nearly every therapeutic area. In specialty medicines, Teva has a
world-leading position in innovative treatments for disorders of
the central nervous system, including pain, as well as a strong
portfolio of respiratory products. Teva integrates its generics and
specialty capabilities in its global research and development
division to create new ways of addressing unmet patient needs by
combining drug development capabilities with devices, services and
technologies. Teva's net revenues in 2015 amounted to $19.7
billion. For more information, visit www.tevapharm.com.
About IBM Watson: Pioneering a New Era of Computing
Watson represents a new era in computing called cognitive
computing, where systems understand the world the way humans do:
through senses, learning, and experience. Watson continuously
learns from previous interactions, gaining in value and knowledge
over time. With Watson, organizations are harnessing the power of
cognitive computing to transform industries, help professionals do
their jobs better, and solve important challenges.
Watson solutions are being built, used and deployed in more than
45 countries and across 20 different industries. Watson is open to
the world, allowing a growing community of developers, students,
entrepreneurs and tech enthusiasts to easily tap into the most
advanced and diverse cognitive computing platform available
today.
About IBM Research
For more than seven decades, IBM Research has defined the future
of information technology with more than 3,000 researchers in 12
labs located across six continents. Scientists from IBM Research
have produced six Nobel Laureates, 10 U.S. National Medals of
Technology, five U.S. National Medals of Science, six Turing
Awards, 19 inductees in the National Academy of Sciences and 20
inductees into the U.S. National Inventors Hall of Fame. For more
information about IBM Research, visit www.ibm.com/research.
Teva's Safe Harbor Statement under the U. S. Private
Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are
based on management’s current beliefs and expectations and involve
a number of known and unknown risks and uncertainties that could
cause our future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include
risks relating to: our ability to develop and commercialize
additional pharmaceutical products; competition for our specialty
products, especially Copaxone® (which faces competition from
orally-administered alternatives and a generic version); our
ability to integrate Allergan plc’s worldwide generic
pharmaceuticals business (“Actavis Generics”) and to realize the
anticipated benefits of the acquisition (and the timing of
realizing such benefits); the fact that following the consummation
of the Actavis Generics acquisition, we are dependent to a much
larger extent than previously on our generic pharmaceutical
business; potential restrictions on our ability to engage in
additional transactions or incur additional indebtedness as a
result of the substantial amount of debt incurred to finance the
Actavis Generics acquisition; the fact that for a period of time
following the Actavis Generics acquisition, we will have
significantly less cash on hand than previously, which could
adversely affect our ability to grow; the possibility of material
fines, penalties and other sanctions and other adverse consequences
arising out of our ongoing FCPA investigations and related matters;
our ability to achieve expected results from investments in our
pipeline of specialty and other products; our ability to identify
and successfully bid for suitable acquisition targets or licensing
opportunities, or to consummate and integrate acquisitions; the
extent to which any manufacturing or quality control problems
damage our reputation for quality production and require costly
remediation; increased government scrutiny in both the U.S. and
Europe of our patent settlement agreements; our exposure to
currency fluctuations and restrictions as well as credit risks; the
effectiveness of our patents, confidentiality agreements and other
measures to protect the intellectual property rights of our
specialty medicines; the effects of reforms in healthcare
regulation and pharmaceutical pricing, reimbursement and coverage;
competition for our generic products, both from other
pharmaceutical companies and as a result of increased governmental
pricing pressures; governmental investigations into sales and
marketing practices, particularly for our specialty pharmaceutical
products; adverse effects of political or economic instability,
major hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with
internal or third-party information technology systems that
adversely affect our complex manufacturing processes; significant
disruptions of our information technology systems or breaches of
our data security; competition for our specialty pharmaceutical
businesses from companies with greater resources and capabilities;
the impact of continuing consolidation of our distributors and
customers; decreased opportunities to obtain U.S. market
exclusivity for significant new generic products; potential
liability in the U.S., Europe and other markets for sales of
generic products prior to a final resolution of outstanding patent
litigation; our potential exposure to product liability claims that
are not covered by insurance; any failure to recruit or retain key
personnel, or to attract additional executive and managerial
talent; any failures to comply with complex Medicare and Medicaid
reporting and payment obligations; significant impairment charges
relating to intangible assets, goodwill and property, plant and
equipment; the effects of increased leverage and our resulting
reliance on access to the capital markets; potentially significant
increases in tax liabilities; the effect on our overall effective
tax rate of the termination or expiration of governmental programs
or tax benefits, or of a change in our business; variations in
patent laws that may adversely affect our ability to manufacture
our products in the most efficient manner; environmental risks; and
other factors that are discussed in our Annual Report on Form 20-F
for the year ended December 31, 2015 and in our other filings with
the U.S. Securities and Exchange Commission (the "SEC").
Forward-looking statements speak only as of the date on which they
are made and we assume no obligation to update or revise any
forward-looking statements or other information, whether as a
result of new information, future events or otherwise.
1 http://dx.doi.org/10.1016/j.drudis.2013.11.005
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161026005557/en/
For Teva:IR Contacts:United StatesKevin C. Mannix,
215-591-8912orRan Meir, 215-591-3033orIsraelTomer
Amitai, 972 (3) 926-7656orPR Contacts:IsraelIris Beck
Codner, 972 (3) 926-7687orUnited StatesDenise Bradley,
215-591-8974orNancy Leone, 215-284-0213orFor IBM:PR
Contacts:IsraelRachel Yaacobi, 972 (3) 9188-752orUnited
StatesLorie Fiber, 646-318-0575orKristi Bond,
802-345-8313
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024